How does ryan specialty make money?

ryan specialty generates $3.0B in annual revenue (annual revenue · their business grew +21.9% last year).

What is RYAN's XVARY composite score?

ryan specialty (RYAN) has an XVARY composite score of 48/100, rated below average. This combines growth, value, risk, and momentum factors.

RYAN — ryan specialty stock analysis

Start here if you're new

what it is

Ryan sells specialty insurance through brokers, and its revenue splits 61% / 26% / 13% across three lines.

how it gets paid

Last year Ryan Specialty made $3.0B in revenue. Wholesale Brokerage was the main engine at $1.83B, or 61% of sales.

why it's growing
Revenue grew 21.9% last year. However, even on a comparable basis, we estimate that profit per share will reach $2.40 this year, up 20% from street expectations of $2.00 in.

what just happened

Ryan beat EPS by 66.67%, posting $0.45 against $0.27 expected.

At a glance

B+ balance sheet — decent shape, but not bulletproof

68.6x trailing p/e — you're paying up for this one

1.0% dividend yield — cash in your pocket every quarter

18.0% return on capital — nothing to write home about

xvary composite: 48/100 — below average

What they do

Ryan sells specialty insurance through brokers, and its revenue splits 61% / 26% / 13% across three lines.

Ryan lives in excess and surplus, where standard carriers say no and brokers still need a quote. That gives you 61% of revenue from wholesale brokerage (the middleman between broker and insurer) and 13% from binding authority (permission to write policies), a gap that shows reach plus control. Return on capital is 18.0%, so every $100 tied up has been throwing off $18 in operating profit.

financials large-cap specialty-insurance broker-distribution valuation

How they make money

$3.0B annual revenue · their business grew +21.9% last year

Wholesale Brokerage

$1.83B

Underwriting Management

$0.78B

Binding Authority

$0.39B

The products that matter

placing specialty insurance

Wholesale Brokerage

$2.3B · about 75% of revenue

it is the center of the business. the latest organic growth figure was 7.1%, which tells you demand is still there even before acquisitions do the heavy lifting.

core fee engine

designing and pricing policies

Managing Underwriting

$0.8B · about 25% of revenue

this is roughly one quarter of a $3.05B company. no separate growth figure was supplied here, which matters because this segment is supposed to help the margin story look better.

deeper client ties

inorganic expansion

Acquisitions

13 pts of growth

acquisitions added 13 percentage points to revenue growth last year. that is more than the 7.1% organic contribution, which tells you scale is being bought as much as built.

roll-up fuel

Key numbers

$74

Target price

That is $22.52 above the current $51.48, so the upside is 44% if the target is right.

68.6x

Trailing P/E

You are paying almost 69 dollars for 1 dollar of trailing earnings, which is rich for a business with a 10.8% net margin.

18.0%

Return on capital

For every $100 tied up in the business, Ryan has been earning about $18 in operating profit.

$3.4B

Debt load

Debt is $3.4B, which is larger than annual revenue by about $400M and leaves less room if rates move higher.

Financial health

B+

strength

balance sheet grade B+ — solid but not elite
risk rank 3 — safer than 50% of stocks
price stability 50 / 100
long-term debt $3.4B (20% of capital)
net profit margin 10.8% — keeps 11 cents of every dollar in revenue
return on equity 11% — $0.11 profit for every $1 investors have put in

B+ — functional but not a standout on the balance sheet.

Total return vs. market

Return history isn't available for RYAN right now.

same standard. no invented return math.

source: institutional data · return history unavailable

What just happened

beat estimates

Ryan beat EPS by 66.67%, posting $0.45 against $0.27 expected.

EDGAR says annual revenue was $3.0B, while the latest quarter was $2.3B. That is a quarter that almost equals the full year, which is exactly the kind of number that makes you look twice.

$2.3B

revenue

$0.45

eps

21.9%

revenue growth

the number that mattered

The $0.18 EPS beat mattered because analysts were low by 66.67%, and that is not a rounding error.

we look for a year of significant growth at ryan specialty in 2026.

our presentation uses adjusted diluted earnings starting in 2026, and previous years are not being restated.
however, even on a comparable basis, we estimate that profit per share will reach $2.40 this year, up 20% from street expectations of $2.00 in adjusted earnings for 2025.
margins are likely to be helped by 16% sales growth, which is likely to handily exceed the rate of expense growth.

there is also ample opportunity for cost synergies, as Ryan integrates the various acquisitions that it has completed in recent months. Ryan occupies a unique niche in the insurance industry. the company is the only publicly traded wholesale broker in the country, and it specializes in the ''excess and surplus'' (e&s) side of the business. the e&s category comprises about a quarter of the industry and consists of risks that are complex or otherwise difficult to place with traditional insurers. some of the risks in this sector include catastrophe losses, climate change issues, large jury verdicts, and novel health matters. margins in this business tend to be higher than in everyday insurance because specialty insurers are subject to less regulation, especially in regions outside of their home state. surplus insurers have more leeway in regard to structuring and tailoring products to the particular needs of their customers, and they also have more freedom with the rates they charge. this typically leads to higher margins for e&s providers. Rising debt levels are becoming a bit of a concern. acquisitions are an important strategy for ryan specialty, and the company has been very active on that front completing over 60 purchases since its founding.
however, the debt-to-equity ratio is now approaching 75%, and cash levels have been depleted by $700 million over the past two years.
we would prefer to see debt reduction as a priority, rather than acquisitions, over the near term.

source: company earnings report, 2026

What could go wrong

the #1 risk is acquisition-heavy growth colliding with delayed margin improvement.

∘

med

Growth is leaning hard on deals

Acquisitions added 13 percentage points to revenue growth, while organic growth was 7.1%. That is not fake growth, but it is more expensive growth and harder to repeat every year.

If deal flow slows or integration misses, the market is left valuing a slower organic grower at a premium multiple.

∘

med

The margin story slipped

Management deferred a 35% margin target. With a 9.2% net profit margin today, investors were counting on better operating leverage than the company has shown so far.

If costs stay sticky, revenue growth will keep outrunning EPS growth — and that usually ends with a lower multiple.

∘

med

68.6x earnings leaves little room for a stumble

This stock already trades at a rich trailing P/E for a broker. You are not buying cheap cash flows. You are buying confidence that execution stays clean.

A normal re-rating hurts even if the business keeps growing. Good companies can still be bad stocks at the wrong price.

∘

med

Debt is manageable until growth slows

Long-term debt sits at $3.4B, or 20% of capital. That is workable with steady fee income. It matters more if acquisitions stop contributing and margins stay soft.

The balance sheet is fine today. It gets less comfortable if the company has to choose between buybacks, deals, and deleveraging.

The combined risk picture is simple: Ryan grew revenue 21.3%, but only 7.1% was organic, EPS rose 6%, and the margin target moved out. That is enough tension to matter when the stock trades at 68.6x earnings.

source: institutional data · regulatory filings · risk analysis

Pay attention to

metric

organic growth staying above the mid-single digits

7.1% is respectable. If that starts with a five or lower, the roll-up premium gets harder to defend.

calendar

next earnings update

You want two things at once: organic growth holding up and more clarity on when the 35% margin target is back on the table.

risk

integration quality on acquired businesses

Acquisitions added 13 points to growth. That only helps if those deals keep clients, producers, and margins intact after closing.

trend

buyback pace versus debt discipline

The $300M authorization matters less as a headline than as a capital allocation signal. You want repurchases without the balance sheet getting sloppier.

Analyst rankings

short-term outlook

below average

momentum score 4 — in human-speak, analysts do not expect this stock to outrun the pack in the next stretch.

risk profile

average

stability score 3 — this sits near the middle on risk, not a bunker stock and not chaos either.

chart momentum

below average

technical score 4 — the chart is not giving bulls much help right now.

source: institutional data

Institutional activity

institutions have been net buying for 3 consecutive quarters — 199 buyers vs. 166 sellers in 3q2025. total institutional holdings: 0.1B shares. net buying for 3 quarters.

source: institutional data · 1q2025-3q2025

source: institutional data

Price targets

3-5 year target range

$45 $103

$51 current price

$74 target midpoint · +44% from current · 3-5yr high: $105 (+105% · 21% ann'l return)

source: institutional data · analyst targets

The deep dive

RYAN

xvary deep dive

ryan

the full analysis is in the works.

what you'll get

dcf valuation model

bull / base / bear scenarios

competitive moat breakdown

quarterly earnings tracker

operating model projections

risk matrix with kill criteria

original price target + conviction

updated with every earnings

free · no spam · you'll be first to read it

ryan

Get this snapshot in your inbox

Want the deeper analysis?